Full Press Release Details
TORONTO and CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- ERN UK
PMN
ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer’s Disease
Key Takeaway: TORONTO and CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- ERN UK
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+98%
120-day peak, hindsight
Typical move
16.6%
average across 4 past catalysts
Cash runway
~15 mo
Low dilution risk
Lead asset
PMN310
Phase 1 · Healthy Participants